Cambridge Antibody Technology Group Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: paradigm7241 who wrote (38)	1/29/2000 12:14:00 AM
From: michael_f_murphy	of 625

A bit of good old American market maker thievery seems at play also. Could you explain "It appears, then, that negative selection against autoreactive B cells is not complete (not a new idea) and in fact somatic hypermutation occurs against self antigens(this is a new idea). Nonetheless, as an immunologist who studies immunoregulatory pathways I have noted that animals (and humans) with Th1 mediated autoimmunity invariably do better if they produce autoantibodies. This phenomenon has been the basis for the model that low affinity autoimmune Th2/3 cells that escape thymic selection are necessary for protection from Th1 mediated autoimmunity. I can discuss this in more detail later if requested" in a little less detail for the slow kid in class. <g> Thanks for the info. Keep it coming!!!!

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next